ASCO 2026: Previewing Updates on ADCs and SERDs in mBC

Published Date: 16 May 2026

Dr Elizabeth Sakach expects ASCO 2026 data on ADCs and SERDs in metastatic breast cancer will focus on frontline use, sequencing, and socioeconomics.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

2.

Early Tislelizumab May Boost PFS in Esophageal Cancer

3.

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

4.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

5.

How to keep your prostate healthy and lower your risk of developing serious problems


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot